DS8201a in HER2+ Patients Previously Treated with T-DM1
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

DS8201a in HER2+ Patients Previously Treated with T-DM1

Sponsor: Daiichi Sankyo, Inc.

Protocol DS8201-A-U301: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS8201A, an Anti-Her2-Antibody Drug Conjugate, Versus Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Pretreated With Prior Standard of Care.